Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis

Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.

PRNewsWire • Jun 9, 2026

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.

PRNewsWire • Jun 8, 2026

Why Is Waters (WAT) Up 8.7% Since Last Earnings Report?

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 3, 2026

Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.

PRNewsWire • Jun 3, 2026

Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics

>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.

PRNewsWire • Jun 1, 2026

Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.

PRNewsWire • Jun 1, 2026

Waters Corporation to Present at the Jefferies Global Healthcare Conference

MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

PRNewsWire • May 18, 2026

Understanding Waters (WAT) Reliance on International Revenue

Examine the evolution of Waters' (WAT) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Zacks Investment Research • May 14, 2026

WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues

Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.

Zacks Investment Research • May 7, 2026